SECsense Logo

Blueprint Medicines Corporation's 8-K Report: Key Updates for Investors

$BPMC
Form 8-K
Filed on: 2024-12-18
Source
Blueprint Medicines Corporation's 8-K Report: Key Updates for Investors

The extracted information from the provided section of the financial report is as follows:

  1. Entity Information:
  • Company Name: Blueprint Medicines Corporation
  • CIK Number: 0001597264
  • SEC File Number: 001-37359
  • EIN: 26-3632015
  • Address: 45 Sidney Street, Cambridge, MA 02139
  • Phone Number: 617-374-7580
  • Stock Symbol: BPMC (traded on NASDAQ)
  1. Filing Type:
  • Filing Form: 8-K (a form used to report major events that shareholders should know about)
  1. Filing Date:
  • Date of Report: December 13, 2024
  1. Common Stock Information:
  • Par Value of Common Stock: $0.001 per share
  1. Period of Report:
  • Start and End Date of the Reporting Period: December 13, 2024

Key Insights:

  • The report indicates a specific date for a significant event or update regarding Blueprint Medicines Corporation, which shareholders and potential investors should review closely.
  • The filing under the 8-K form suggests that there may be noteworthy developments or changes in the company that could impact its operations or financial status.
  • The detail about the company's common stock indicates a very low par value, which is typical for many growth-oriented biotech firms.

Importance for Stakeholders:

  • Investors should pay attention to the 8-K filing as it may contain critical information that could affect investment decisions or stock valuation.
  • Analysts may want to assess any accompanying disclosures in the 8-K to understand the context of the report and its implications for the company’s future performance.